The group's principal activity is to provide a portfolio of technologies and expertise for pharmaceutical partners to improve drug. The technologies are designed to improve either the performance of a drug molecule or how the drug is delivered. The group operates in three technology platforms. Advanced peglation technology is designed to enhance the efficacy and performance of most drug classes including macromolecules such as peptides and proteins along with small molecules and other drugs. Pulmonary technology enables the efficient and reproducible deep lung delivery of particles and greater lung deposition in a single breath. Supercritical fluid technology uses substances such as carbon dioxide at elevated temperatures and pressures as non-solvents to control the formation of powder particles for a wide variety of chemical substances. The group has international operations in the United Kingdom and other European countries.
